Bio-Rad(US:BIO) Yahoo Finance·2025-10-23 15:44Group 1: Fund Performance - Upslope Capital Management reported a strong performance in Q3 2025, achieving a net return of +8.8%, outperforming the S&P Midcap 400 ETF (+5.5%) and HFRX Equity Hedge Index (+3.8%) [1] Group 2: Bio-Rad Laboratories, Inc. Overview - Bio-Rad Laboratories, Inc. is a leading global producer of clinical diagnostic and life sciences products, with approximately 70% of its sales being recurring or consumable [3] - As of October 22, 2025, Bio-Rad's stock closed at $331.27, with a market capitalization of $8.789 billion [2] Group 3: Investment Insights on Bio-Rad - Bio-Rad owns over 35% of Sartorius, a Germany-based company, which significantly contributes to its enterprise value, implying an undervaluation of Bio-Rad's core business [3] - The underlying valuation of Bio-Rad is considered attractive at 9x 2026 EBITDA when accounting for its stake in Sartorius, especially in light of potential recovery in fundamentals [3] Group 4: Hedge Fund Interest - Bio-Rad was held by 42 hedge fund portfolios at the end of Q2 2025, an increase from 36 in the previous quarter, indicating growing interest among institutional investors [4]